Abstract:Multiple combinations of antiretroviral drugs have remarkably improved the treatment of HIV-1 infection. However, life-long treatments and drug resistance are still an open issue that requires continuous efforts for the identification of novel antiviral drugs. Background: The reverse transcriptase-associated ribonuclease H (RNase H) hydrolyzes the HIV genome to allow synthesizing viral DNA. Currently, no RNase H inhibitors (RHIs) have reached the clinical phase. Therefore, RNase H can be defined as an attractive target for drug design. Objective: Despite the wealth of information available for RNase H domain, the development of RHIs with high specificity and low cellular toxicity has been disappointing. However, it is now becoming increasingly evident that reverse transcriptase is a highly versatile enzyme, undergoing major structural alterations to complete its catalysis, and that exists a close spatial and temporal interplay between reverse transcriptase polymerase and RNase H domains. This review sums up the present challenges in targeting RNase H encompassing the challenges in selectively inhibiting RNase H vs polymerase and/or HIV-1 integrase and the weak antiviral activity of active site inhibitors, probably for a substrate barrier that impedes small molecules to reach the targeted site. Moreover, the focus is given on the most recent progress in the field of medicinal chemistry that has led to the identification of several small molecules as RHIs in the last few years. Conclusion: RHIs could be a new class of drugs with a novel mechanism of action highly precious for the treatment of resistant HIV strains.

Update on Recent Developments in Small Molecular HIV-1 RNase H Inhibitors (2013-2016): Opportunities and Challenges

Small-molecule Inhibitors of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Function: Challenges and Recent Developments

Recent Progress in the Research of Small Molecule HIV-1 RNase H Inhibitors.

Current Medicinal Chemistry Strategies in the Discovery of Novel HIV-1 Ribonuclease H Inhibitors

Recent advances in the research of HIV-1 RNase H inhibitors.

Deciphering the enigmas of non‐nucleoside reverse transcriptase inhibitors (NNRTIs): A medicinal chemistry expedition towards combating HIV drug resistance

Recent advances on dual inhibitors targeting HIV reverse transcriptase associated polymerase and ribonuclease H

Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: a Patent Review (2005 – 2010)

Recent advances in the discovery and development of novel HIV-1 NNRTI platforms (Part II): 2009-2013 update

Recent Developments in Small Molecular HIV‐1 and Hepatitis B Virus RNase H Inhibitors

Recent Advances in Computer-aided Antiviral Drug Design Targeting HIV-1 Integrase and Reverse Transcriptase Associated Ribonuclease H

Recent Advances in the Discovery and Development of Novel HIV-1 NNRTI Platforms: 2006-2008 Update

Synthetic approaches and application of clinically approved small-molecule Anti-HIV drugs: An update

Recent Progress in Small Molecule CCR5 Antagonists As Potential HIV-1 Entry Inhibitors

Advances in Non-Peptidomimetic HIV Protease Inhibitors.

"Old Dogs with New Tricks": Exploiting Alternative Mechanisms of Action and New Drug Design Strategies for Clinically Validated HIV Targets.

Current state-of-the-art in preclinical and clinical development of novel non-nucleoside HIV-1 reverse transcriptase inhibitors

Contemporary Medicinal Chemistry Strategies for the Discovery and Development of Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors

"Old Dogs with New Tricks": exploiting alternative mechanisms of action and new drug design strategies for clinically validated HIV targets.

Recent discoveries in HIV-1 reverse transcriptase inhibitors

Progress on HIV-1 RT inhibitors with novel mechanism of action